Abstract-In pentobarbital-anesthetized dogs, the increase in the renal norepineph rine secretion rate elicited by renal nerve stimulation (1 Hz) during infusion of angiotensin I (15 ng/kg/min) was partially but significantly inhibited (by 21-37%) after dosing with cilazaprilat (0.1 mg/kg), an angiotensin converting enzyme inhibitor, accompanied by a decrease in the renal venous plasma norepinephrine concentration.
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These results may suggest that cilazaprilat exerts at least a part of its hypotensive effect through decreasing the facilitatory action of endogenous angiotensin I I on adrenergic transmission.
It has been well-documented that exoge nously administered angiotensin II (All) can facilitate sympathetic nerve function through multiple mechanisms (1) (2) (3) (4) ). An attenuation of sympathetic nerve function would occur following any procedure which inhibits the formation of endogenous All.
sufficient level of All would be attained by intravenous infusion of angiotensin I (Al) in pentobarbital-anesthetized dogs. Eight mongrel dogs of both sexes, weighing from 12.5 to 20 kg (15.4+1.0 kg), were anesthetized with intravenous pentobarbital sodium (30 mg/kg and supplemental infusion at 5 mg/kg/hr).
The surgical procedures for preparation were similar to those previously described elsewhere (8). Briefly, the left kidney was exposed, and a platinum electrode was mounted on the distal cut end of the renal bundle as the means of delivering electrical RNS. Renal blood flow (RBF) was measured by a square wave-electromagnetic flow-meter through a non-cannulating flow-probe at tached to the origin of the left renal artery. Simultaneous collection of renal venous and arterial blood was performed through can nulae inserted into the renal vein and the left brachial artery, respectively.
Infusions of Al and injections of CIL were given into the right and left cephalic vein, respectively. Mean arterial blood pressure (ABP) was monitored at the right brachial artery. Heart rate (HR) was measured by an ECG (limb lead II). The plasma NE concentration (NEC) was determined with an amperometric de tector after catecholamine separation by HPLC as previously described (9). After the end of the perfusion experiment, the kidney weight was measured for the calculation of RBF, renal vascular resistance (RVR) and NE secretion rate (NE-SR) on the basis of kidney wet weight; NE-SR was calculated as the product of the renal venous-arterial plasma NEC difference and renal plasma flow. Renal plasma flow was determined as the product of the RBF and the value of one minus hematocrit.
Cilazaprilat (CIL) was kindly provided by Nippon Roche Co., Ltd.; it was dissolved in 0.1 N Na2CO3 and the pH adjusted to 7.0. Angiotensin I (['Asp-511e]-Al), purchased from Osaka Protein Foundation, was dis solved in 0.9% saline. All values are expressed as the mean±S.E. Analysis of variance was employed for the overall statistical analysis, and Tukey's test was used for the statistical analysis of values at each blood sampling point. A P level of less than 0.05 was con sidered to be significant.
After completion of the preparatory surgi cal procedures, an interval of 60-90 min was allowed for the stabilization of cardiovascular variables. Control arterial and renal venous blood samples (3 ml each) were obtained and intravenous infusion of Al (15 ng/kg/min) was started and maintained throughout the experiment. From 15 min after the start of Al infusion, RNS (pulse rate 1 Hz, supramaximal voltage 10-15 V, pulse duration 1 msec) was carried out continuously for approximately 20 min. Ten minutes after the start of RNS during infusion of Al, an intravenous injection of CIL (0.1 mg/kg) was interposed. Periodic blood-sampling was repeated at the following times: just before and 5 min after the start of RNS and just before and 5 and 10 min after administration of CIL, respectively. The results are shown in Table 1 
